CytRx, NAS, ExpressOn BioSystems and Genome Explorations, and CSIRO and Bayer CropScience | GenomeWeb

CytRx Delays Nasdaq Delisting, Changes Subsidiary Name

CytRx said this week that it has postponed the delisting of its stock from the Nasdaq Small Cap Market, stemming from the company’s failure to file its 10-K annual report for 2003, by requesting a hearing with the Nasdaq Qualifications Panel.

That hearing is set for May 13, said CytRx.

The company previously said it received a letter from the Nasdaq on April 19 warning of the possibility of delisting. Pending that hearing, CytRx’s stock will continue to trade under the symbol “CYTRE.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.